

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT

PRINCIPAL FINANCIAL INFORMATION OF CR DOUBLE-CRANE FOR THE YEAR ENDED 31 DECEMBER 2024

On 19 March 2025, Double-Crane released its annual report for the year ended 31 December 2024.

China Resources Double-Crane Pharmaceutical Co., Ltd. (華潤雙鶴藥業股份有限公司) (“**CR Double-Crane**”) is a company incorporated in the People’s Republic of China. The shares of CR Double-Crane are listed on the Shanghai Stock Exchange. As of the date of this announcement, CR Double-Crane is indirectly owned as to 60.24% by China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) and is a subsidiary of the Company.

On 19 March 2025, CR Double-Crane released its annual report for the year ended 31 December 2024 (the “**CR Double-Crane Audited Annual Financials**”). Set out below are the key financial information of the CR Double-Crane Audited Annual Financials:

	As of 31 December 2024 (RMB) (Audited)	As of 31 December 2023 (RMB) (Audited) (Restated)	Decrease (%)
Total assets	16,685,995,679.77	18,202,533,078.60	-8.33%
Net assets attributable to shareholders of the listed company	10,407,864,932.00	12,213,332,138.91	-14.78%

	For the year ended 31 December		Increase/decrease (%)
	2024 (RMB) (Audited)	2023 (RMB) (Audited) (Restated)	
Revenue	11,211,623,666.19	11,310,143,640.49	-0.87%
Net profit attributable to the shareholders of the listed company	1,627,718,404.74	1,670,383,409.39	-2.55%
Net profit attributable to the shareholders of the listed company (excluding extraordinary gains or losses)	1,432,147,436.57	1,233,101,092.60	16.14%
Net cash flow from operating activities	1,825,115,191.24	1,859,057,344.72	-1.83%
Basic earnings per share (RMB/share)	1.5838	1.6306	-2.87%
Diluted earnings per share (RMB/share)	1.5838	1.6306	-2.87%
Weighted average return on net asset (%)	15.07%	13.27%	1.8 percentage point

As determined by the board of directors of CR Double-Crane, CR Double-Crane proposed to distribute a cash dividend of RMB3.71 (inclusive of tax) for every 10 shares to all shareholders of CR Double-Crane based on the total share capital registered on the future record date of equity distribution. Such proposal shall be submitted for shareholders' approval at CR Double-Crane's 2024 annual general meeting.

The CR Double-Crane Audited Annual Financials have been prepared and audited in accordance with the PRC Generally Accepted Accounting Principles. The financial information is limited to CR Double-Crane only and does not represent or provide a complete view of the operational or financial status of the Group. **Shareholders and potential investors should exercise caution when dealing in securities of the Company and should not rely solely on such information.**

For further details of the CR Double-Crane Audited Annual Financials, please refer to the annual report for the year ended 31 December 2024 published by CR Double-Crane on the website of the Shanghai Stock Exchange (www.sse.com.cn).

By order of the Board of Directors
China Resources Pharmaceutical Group Limited
Bai Xiaosong
Chairman

PRC, 19 March 2025

As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive Director; Mr. Tao Ran and Mdm. Deng Rong as executive Directors; Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Guo Chuan and Mdm. Jiao Ruifang as non-executive Directors; and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.